The case for & against
Bull & Bear analysis
Bullish
Organon & Co. (NYSE: OGN) is a global healthcare company specializing in women's health and biosimilars. The company aims to enhance patient care by focusing on innovative solutions and therapies that target women’s health issues. Its portfolio includes established brands and new entrants, like Nexplanon, positioning it as a key player in a growing market for women’s health. Despite facing challenges due to product exclusivity losses and evolving regulatory environments, Organon continues to anticipate strong revenue growth from its core products.
Bull says
- ↑Nexplanon drove 17% YoY growth and received a five-year U.S. label extension.
- ↑Hedlima biosimilar sales up 63% YTD, reflecting successful pricing and market positioning.
- ↑Cost-cuts targeting $200M savings in 2025 drive adjusted EBITDA margin to 32.3%.
- ↑2026 revenue guidance raised to $6.2–6.25B; international sales expected to offset U.S. headwinds.
- ↑Earnings yield at 1.75 and dividend yield at 0.45% indicate attractive valuation.
- ↑Strong liquidity and profitability factors underpin financial resilience amid market pressures.
Bear says
- ↓Adizet exclusivity loss trims ~$200M revenue; Nexplanon sales down high single digits.
- ↓Biosimilar pricing competition to compress adjusted gross margins toward 60–61%.
- ↓Net leverage of 4.3x and low institutional ownership signal balance sheet vulnerabilities.
- ↓Analyst consensus price targets below current levels amid growth and revision uncertainties.
- ↓Foreign exchange headwinds could cost ~$200M in 2025; policy changes limit access.
- ↓Restructuring-related SG&A uptick of ~0.5 percentage point may pressure margins.
Investment themes with OGN
High Dividend Yield↓ -0.51%
Companies paying above-average dividends
AVGO · JPM · XOM
Pharmaceuticals↓ -0.48%
Drug development driving global healthcare solutions
JNJ · LLY · RPRX
Earnings Call · Q4 2024 · Mgmt. Guidance
Updated 08-17-2026neutral
Transcript signals
Bull points
- $26 million transaction loss in foreign exchange. More than half of that, or $15 million, was in the latter part of the fourth quarter after our last update to earnings guidance and related to significant devaluation in unhedgeable currencies, about half of that impact coming from the ruble. This compares favorably to full year 2023, where we realized $43 million of losses on foreign exchange.
- we delivered $967 million of free cash flow before one-time cost in 2024, which met our expectation from the start of the year. In the top half of the table, the number that stands out in free cash flow before one-time items is cash taxes, which were higher in 2024 as we expected due to the payment of certain non-U.S. taxes, as well as settlements in various jurisdictions that triggered higher cash taxes relative to 2023, which happened to be an unusually low year for cash taxes.
- As the quarters roll out in 2025, we expect our sequential P&L performance to improve throughout the year, which should provide a window into the strength of the underlying business beyond the LOE impact, which we expect to see in the near term here in 2025.
Bear points
- Reported net income for full year 2024 was $864 million, or $3.33 per diluted share, compared with $1,023,000,000, or $3.99 per diluted share in 2023. And that difference is due to a prior year one-time benefit from the termination of a Swiss tax arrangement.
- we expect adjusted gross margin to be in the range of 60 to 61%, about a point lower at the midpoint compared to last year, and that's a continuation of the pressure on gross margin that we saw in 2024, especially in the back half due to price and higher manufacturing and distribution costs.
- flat revenue performance in 2025. That is reflective of an approximate $200 million headwind from Adizet's loss of exclusivity in Europe, which we will look to offset with growth in products like Vitamma, Emgality, Fertility, and of course, Nexplanon.
Read full transcript analysis ›